nodes	percent_of_prediction	percent_of_DWPC	metapath
Valrubicin—Doxorubicin—kidney cancer	0.376	1	CrCtD
Valrubicin—urinary bladder cancer—kidney cancer	0.308	1	CtDrD
Valrubicin—Daunorubicin—Doxorubicin—kidney cancer	0.0793	0.333	CrCrCtD
Valrubicin—Epirubicin—Doxorubicin—kidney cancer	0.0793	0.333	CrCrCtD
Valrubicin—Idarubicin—Doxorubicin—kidney cancer	0.0793	0.333	CrCrCtD
Valrubicin—TOP2A—Doxorubicin—kidney cancer	0.0359	1	CbGbCtD
Valrubicin—Epirubicin—AURKA—kidney cancer	0.000848	0.534	CrCbGaD
Valrubicin—Doxorubicin—AURKA—kidney cancer	0.000487	0.307	CrCbGaD
Valrubicin—TOP2A—Gastric Cancer Network 1—TPX2—kidney cancer	0.000409	0.164	CbGpPWpGaD
Valrubicin—TOP2A—Docetaxel—Paclitaxel—kidney cancer	0.000336	0.227	CbGdCrCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—HLTF—kidney cancer	0.000263	0.106	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FOSL2—kidney cancer	0.000248	0.0993	CbGpPWpGaD
Valrubicin—TOP2A—Vindesine—Vincristine—kidney cancer	0.000171	0.115	CbGdCrCtD
Valrubicin—TOP2A—Vindesine—Vinblastine—kidney cancer	0.000171	0.115	CbGdCrCtD
Valrubicin—TOP2A—Gefitinib—Erlotinib—kidney cancer	0.000161	0.109	CbGdCrCtD
Valrubicin—TOP2A—Gastric Cancer Network 1—AURKA—kidney cancer	0.000138	0.0555	CbGpPWpGaD
Valrubicin—Daunorubicin—CYP1A1—kidney cancer	0.000129	0.0812	CrCbGaD
Valrubicin—Anaemia—Everolimus—kidney cancer	0.000123	0.00337	CcSEcCtD
Valrubicin—Pneumonia—Vincristine—kidney cancer	0.000121	0.00331	CcSEcCtD
Valrubicin—Malaise—Vinblastine—kidney cancer	0.00012	0.0033	CcSEcCtD
Valrubicin—Malaise—Everolimus—kidney cancer	0.00012	0.00329	CcSEcCtD
Valrubicin—Gastrointestinal pain—Temsirolimus—kidney cancer	0.000119	0.00327	CcSEcCtD
Valrubicin—Hyperglycaemia—Gemcitabine—kidney cancer	0.000115	0.00316	CcSEcCtD
Valrubicin—Abdominal pain—Temsirolimus—kidney cancer	0.000115	0.00316	CcSEcCtD
Valrubicin—Body temperature increased—Temsirolimus—kidney cancer	0.000115	0.00316	CcSEcCtD
Valrubicin—Pneumonia—Gemcitabine—kidney cancer	0.000115	0.00314	CcSEcCtD
Valrubicin—Chest pain—Everolimus—kidney cancer	0.000113	0.0031	CcSEcCtD
Valrubicin—Myalgia—Everolimus—kidney cancer	0.000113	0.0031	CcSEcCtD
Valrubicin—Gastrointestinal pain—Pazopanib—kidney cancer	0.000112	0.00308	CcSEcCtD
Valrubicin—Discomfort—Vinblastine—kidney cancer	0.000112	0.00308	CcSEcCtD
Valrubicin—Discomfort—Everolimus—kidney cancer	0.000112	0.00307	CcSEcCtD
Valrubicin—Ageusia—Doxorubicin—kidney cancer	0.000112	0.00305	CcSEcCtD
Valrubicin—Flatulence—Sunitinib—kidney cancer	0.000109	0.003	CcSEcCtD
Valrubicin—Chest pain—Erlotinib—kidney cancer	0.000109	0.00299	CcSEcCtD
Valrubicin—Myalgia—Erlotinib—kidney cancer	0.000109	0.00299	CcSEcCtD
Valrubicin—Haematuria—Gemcitabine—kidney cancer	0.000109	0.00298	CcSEcCtD
Valrubicin—Abdominal pain—Pazopanib—kidney cancer	0.000109	0.00298	CcSEcCtD
Valrubicin—TOP2A—Vinorelbine—Vinblastine—kidney cancer	0.000108	0.0728	CbGdCrCtD
Valrubicin—TOP2A—Vinorelbine—Vincristine—kidney cancer	0.000108	0.0728	CbGdCrCtD
Valrubicin—Back pain—Sunitinib—kidney cancer	0.000107	0.00294	CcSEcCtD
Valrubicin—Anaemia—Sorafenib—kidney cancer	0.000107	0.00292	CcSEcCtD
Valrubicin—Asthenia—Temsirolimus—kidney cancer	0.000105	0.00287	CcSEcCtD
Valrubicin—Pruritus—Temsirolimus—kidney cancer	0.000103	0.00283	CcSEcCtD
Valrubicin—Vasodilation procedure—Doxorubicin—kidney cancer	0.000103	0.00282	CcSEcCtD
Valrubicin—Vasodilation—Doxorubicin—kidney cancer	0.000103	0.00282	CcSEcCtD
Valrubicin—Anaemia—Sunitinib—kidney cancer	0.000103	0.00281	CcSEcCtD
Valrubicin—Oedema peripheral—Gemcitabine—kidney cancer	0.000101	0.00276	CcSEcCtD
Valrubicin—Dysuria—Paclitaxel—kidney cancer	0.0001	0.00274	CcSEcCtD
Valrubicin—Diarrhoea—Temsirolimus—kidney cancer	9.99e-05	0.00274	CcSEcCtD
Valrubicin—Pollakiuria—Paclitaxel—kidney cancer	9.9e-05	0.00271	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Everolimus—kidney cancer	9.89e-05	0.00271	CcSEcCtD
Valrubicin—Asthenia—Pazopanib—kidney cancer	9.87e-05	0.0027	CcSEcCtD
Valrubicin—Myalgia—Sorafenib—kidney cancer	9.83e-05	0.00269	CcSEcCtD
Valrubicin—Ill-defined disorder—Dactinomycin—kidney cancer	9.76e-05	0.00267	CcSEcCtD
Valrubicin—Nocturia—Doxorubicin—kidney cancer	9.74e-05	0.00267	CcSEcCtD
Valrubicin—Pruritus—Pazopanib—kidney cancer	9.73e-05	0.00267	CcSEcCtD
Valrubicin—Anaemia—Dactinomycin—kidney cancer	9.72e-05	0.00266	CcSEcCtD
Valrubicin—Irritability—Capecitabine—kidney cancer	9.71e-05	0.00266	CcSEcCtD
Valrubicin—Urinary retention—Capecitabine—kidney cancer	9.67e-05	0.00265	CcSEcCtD
Valrubicin—Hyperglycaemia—Paclitaxel—kidney cancer	9.66e-05	0.00265	CcSEcCtD
Valrubicin—Dizziness—Temsirolimus—kidney cancer	9.65e-05	0.00264	CcSEcCtD
Valrubicin—Pneumonia—Paclitaxel—kidney cancer	9.61e-05	0.00263	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Erlotinib—kidney cancer	9.54e-05	0.00261	CcSEcCtD
Valrubicin—Malaise—Dactinomycin—kidney cancer	9.49e-05	0.0026	CcSEcCtD
Valrubicin—Chest pain—Sunitinib—kidney cancer	9.46e-05	0.00259	CcSEcCtD
Valrubicin—Myalgia—Sunitinib—kidney cancer	9.46e-05	0.00259	CcSEcCtD
Valrubicin—Diarrhoea—Pazopanib—kidney cancer	9.41e-05	0.00258	CcSEcCtD
Valrubicin—Urinary tract infection—Paclitaxel—kidney cancer	9.29e-05	0.00254	CcSEcCtD
Valrubicin—Vomiting—Temsirolimus—kidney cancer	9.28e-05	0.00254	CcSEcCtD
Valrubicin—TOP2A—Vincristine—Vinblastine—kidney cancer	9.22e-05	0.0623	CbGdCrCtD
Valrubicin—Rash—Temsirolimus—kidney cancer	9.2e-05	0.00252	CcSEcCtD
Valrubicin—Dermatitis—Temsirolimus—kidney cancer	9.19e-05	0.00252	CcSEcCtD
Valrubicin—Headache—Temsirolimus—kidney cancer	9.14e-05	0.0025	CcSEcCtD
Valrubicin—Haematuria—Paclitaxel—kidney cancer	9.11e-05	0.00249	CcSEcCtD
Valrubicin—Dizziness—Pazopanib—kidney cancer	9.09e-05	0.00249	CcSEcCtD
Valrubicin—Back pain—Vincristine—kidney cancer	9.09e-05	0.00249	CcSEcCtD
Valrubicin—Feeling abnormal—Vinblastine—kidney cancer	8.98e-05	0.00246	CcSEcCtD
Valrubicin—Myalgia—Dactinomycin—kidney cancer	8.96e-05	0.00245	CcSEcCtD
Valrubicin—Feeling abnormal—Everolimus—kidney cancer	8.95e-05	0.00245	CcSEcCtD
Valrubicin—Gastrointestinal pain—Vinblastine—kidney cancer	8.91e-05	0.00244	CcSEcCtD
Valrubicin—Gastrointestinal pain—Everolimus—kidney cancer	8.88e-05	0.00243	CcSEcCtD
Valrubicin—Discomfort—Dactinomycin—kidney cancer	8.85e-05	0.00242	CcSEcCtD
Valrubicin—Cystitis noninfective—Doxorubicin—kidney cancer	8.82e-05	0.00242	CcSEcCtD
Valrubicin—Vomiting—Pazopanib—kidney cancer	8.74e-05	0.0024	CcSEcCtD
Valrubicin—Cystitis—Doxorubicin—kidney cancer	8.72e-05	0.00239	CcSEcCtD
Valrubicin—Anaemia—Vincristine—kidney cancer	8.69e-05	0.00238	CcSEcCtD
Valrubicin—Rash—Pazopanib—kidney cancer	8.67e-05	0.00238	CcSEcCtD
Valrubicin—Nausea—Temsirolimus—kidney cancer	8.67e-05	0.00238	CcSEcCtD
Valrubicin—Dermatitis—Pazopanib—kidney cancer	8.66e-05	0.00237	CcSEcCtD
Valrubicin—Back pain—Gemcitabine—kidney cancer	8.62e-05	0.00236	CcSEcCtD
Valrubicin—Abdominal pain—Vinblastine—kidney cancer	8.62e-05	0.00236	CcSEcCtD
Valrubicin—Headache—Pazopanib—kidney cancer	8.61e-05	0.00236	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Sorafenib—kidney cancer	8.59e-05	0.00235	CcSEcCtD
Valrubicin—Abdominal pain—Everolimus—kidney cancer	8.58e-05	0.00235	CcSEcCtD
Valrubicin—Body temperature increased—Everolimus—kidney cancer	8.58e-05	0.00235	CcSEcCtD
Valrubicin—Gastrointestinal pain—Erlotinib—kidney cancer	8.57e-05	0.00235	CcSEcCtD
Valrubicin—Blood urea increased—Doxorubicin—kidney cancer	8.53e-05	0.00234	CcSEcCtD
Valrubicin—Oedema peripheral—Paclitaxel—kidney cancer	8.45e-05	0.00231	CcSEcCtD
Valrubicin—Body temperature increased—Erlotinib—kidney cancer	8.28e-05	0.00227	CcSEcCtD
Valrubicin—Abdominal pain—Erlotinib—kidney cancer	8.28e-05	0.00227	CcSEcCtD
Valrubicin—Ill-defined disorder—Gemcitabine—kidney cancer	8.27e-05	0.00227	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Sunitinib—kidney cancer	8.26e-05	0.00226	CcSEcCtD
Valrubicin—Anaemia—Gemcitabine—kidney cancer	8.24e-05	0.00226	CcSEcCtD
Valrubicin—Dysuria—Capecitabine—kidney cancer	8.22e-05	0.00225	CcSEcCtD
Valrubicin—Nausea—Pazopanib—kidney cancer	8.17e-05	0.00224	CcSEcCtD
Valrubicin—Bladder pain—Doxorubicin—kidney cancer	8.17e-05	0.00224	CcSEcCtD
Valrubicin—Malaise—Gemcitabine—kidney cancer	8.04e-05	0.0022	CcSEcCtD
Valrubicin—Myalgia—Vincristine—kidney cancer	8e-05	0.00219	CcSEcCtD
Valrubicin—Hyperglycaemia—Capecitabine—kidney cancer	7.93e-05	0.00217	CcSEcCtD
Valrubicin—Pneumonia—Capecitabine—kidney cancer	7.88e-05	0.00216	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Dactinomycin—kidney cancer	7.82e-05	0.00214	CcSEcCtD
Valrubicin—Asthenia—Vinblastine—kidney cancer	7.82e-05	0.00214	CcSEcCtD
Valrubicin—Asthenia—Everolimus—kidney cancer	7.79e-05	0.00213	CcSEcCtD
Valrubicin—Gastrointestinal pain—Sorafenib—kidney cancer	7.71e-05	0.00211	CcSEcCtD
Valrubicin—Pruritus—Everolimus—kidney cancer	7.68e-05	0.0021	CcSEcCtD
Valrubicin—Urinary tract infection—Capecitabine—kidney cancer	7.62e-05	0.00209	CcSEcCtD
Valrubicin—Myalgia—Gemcitabine—kidney cancer	7.59e-05	0.00208	CcSEcCtD
Valrubicin—Chest pain—Gemcitabine—kidney cancer	7.59e-05	0.00208	CcSEcCtD
Valrubicin—Asthenia—Erlotinib—kidney cancer	7.52e-05	0.00206	CcSEcCtD
Valrubicin—Discomfort—Gemcitabine—kidney cancer	7.5e-05	0.00205	CcSEcCtD
Valrubicin—Haematuria—Capecitabine—kidney cancer	7.47e-05	0.00205	CcSEcCtD
Valrubicin—Diarrhoea—Vinblastine—kidney cancer	7.46e-05	0.00204	CcSEcCtD
Valrubicin—Abdominal pain—Sorafenib—kidney cancer	7.45e-05	0.00204	CcSEcCtD
Valrubicin—Body temperature increased—Sorafenib—kidney cancer	7.45e-05	0.00204	CcSEcCtD
Valrubicin—Diarrhoea—Everolimus—kidney cancer	7.43e-05	0.00204	CcSEcCtD
Valrubicin—TOP2A—Vinblastine—Vincristine—kidney cancer	7.42e-05	0.0501	CbGdCrCtD
Valrubicin—Gastrointestinal pain—Sunitinib—kidney cancer	7.42e-05	0.00203	CcSEcCtD
Valrubicin—Pruritus—Erlotinib—kidney cancer	7.41e-05	0.00203	CcSEcCtD
Valrubicin—Flatulence—Paclitaxel—kidney cancer	7.36e-05	0.00202	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 1—APC—kidney cancer	7.32e-05	0.0294	CbGpPWpGaD
Valrubicin—Back pain—Paclitaxel—kidney cancer	7.22e-05	0.00198	CcSEcCtD
Valrubicin—Dizziness—Vinblastine—kidney cancer	7.21e-05	0.00197	CcSEcCtD
Valrubicin—Dizziness—Everolimus—kidney cancer	7.18e-05	0.00197	CcSEcCtD
Valrubicin—Body temperature increased—Sunitinib—kidney cancer	7.17e-05	0.00196	CcSEcCtD
Valrubicin—Abdominal pain—Sunitinib—kidney cancer	7.17e-05	0.00196	CcSEcCtD
Valrubicin—Diarrhoea—Erlotinib—kidney cancer	7.17e-05	0.00196	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—kidney cancer	7.13e-05	0.0286	CbGpPWpGaD
Valrubicin—Feeling abnormal—Dactinomycin—kidney cancer	7.07e-05	0.00194	CcSEcCtD
Valrubicin—Gastrointestinal pain—Dactinomycin—kidney cancer	7.02e-05	0.00192	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Vincristine—kidney cancer	6.99e-05	0.00191	CcSEcCtD
Valrubicin—Oedema peripheral—Capecitabine—kidney cancer	6.93e-05	0.0019	CcSEcCtD
Valrubicin—Vomiting—Vinblastine—kidney cancer	6.93e-05	0.0019	CcSEcCtD
Valrubicin—Dizziness—Erlotinib—kidney cancer	6.93e-05	0.0019	CcSEcCtD
Valrubicin—Ill-defined disorder—Paclitaxel—kidney cancer	6.93e-05	0.0019	CcSEcCtD
Valrubicin—Vomiting—Everolimus—kidney cancer	6.9e-05	0.00189	CcSEcCtD
Valrubicin—Anaemia—Paclitaxel—kidney cancer	6.9e-05	0.00189	CcSEcCtD
Valrubicin—Daunorubicin—ABCB1—kidney cancer	6.85e-05	0.0432	CrCbGaD
Valrubicin—Rash—Everolimus—kidney cancer	6.85e-05	0.00188	CcSEcCtD
Valrubicin—Dermatitis—Everolimus—kidney cancer	6.84e-05	0.00187	CcSEcCtD
Valrubicin—Headache—Vinblastine—kidney cancer	6.83e-05	0.00187	CcSEcCtD
Valrubicin—Headache—Everolimus—kidney cancer	6.8e-05	0.00186	CcSEcCtD
Valrubicin—Abdominal pain—Dactinomycin—kidney cancer	6.79e-05	0.00186	CcSEcCtD
Valrubicin—Body temperature increased—Dactinomycin—kidney cancer	6.79e-05	0.00186	CcSEcCtD
Valrubicin—Asthenia—Sorafenib—kidney cancer	6.76e-05	0.00185	CcSEcCtD
Valrubicin—Malaise—Paclitaxel—kidney cancer	6.73e-05	0.00184	CcSEcCtD
Valrubicin—Pruritus—Sorafenib—kidney cancer	6.67e-05	0.00183	CcSEcCtD
Valrubicin—Vomiting—Erlotinib—kidney cancer	6.66e-05	0.00182	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Gemcitabine—kidney cancer	6.63e-05	0.00182	CcSEcCtD
Valrubicin—Rash—Erlotinib—kidney cancer	6.61e-05	0.00181	CcSEcCtD
Valrubicin—Dermatitis—Erlotinib—kidney cancer	6.6e-05	0.00181	CcSEcCtD
Valrubicin—Headache—Erlotinib—kidney cancer	6.56e-05	0.0018	CcSEcCtD
Valrubicin—Asthenia—Sunitinib—kidney cancer	6.51e-05	0.00178	CcSEcCtD
Valrubicin—Nausea—Vinblastine—kidney cancer	6.47e-05	0.00177	CcSEcCtD
Valrubicin—Nausea—Everolimus—kidney cancer	6.45e-05	0.00177	CcSEcCtD
Valrubicin—Diarrhoea—Sorafenib—kidney cancer	6.45e-05	0.00177	CcSEcCtD
Valrubicin—Pruritus—Sunitinib—kidney cancer	6.42e-05	0.00176	CcSEcCtD
Valrubicin—Chest pain—Paclitaxel—kidney cancer	6.36e-05	0.00174	CcSEcCtD
Valrubicin—Myalgia—Paclitaxel—kidney cancer	6.36e-05	0.00174	CcSEcCtD
Valrubicin—Discomfort—Paclitaxel—kidney cancer	6.28e-05	0.00172	CcSEcCtD
Valrubicin—Gastrointestinal pain—Vincristine—kidney cancer	6.27e-05	0.00172	CcSEcCtD
Valrubicin—Dizziness—Sorafenib—kidney cancer	6.23e-05	0.00171	CcSEcCtD
Valrubicin—Nausea—Erlotinib—kidney cancer	6.22e-05	0.0017	CcSEcCtD
Valrubicin—Diarrhoea—Sunitinib—kidney cancer	6.21e-05	0.0017	CcSEcCtD
Valrubicin—Asthenia—Dactinomycin—kidney cancer	6.16e-05	0.00169	CcSEcCtD
Valrubicin—Abdominal pain—Vincristine—kidney cancer	6.06e-05	0.00166	CcSEcCtD
Valrubicin—Body temperature increased—Vincristine—kidney cancer	6.06e-05	0.00166	CcSEcCtD
Valrubicin—TOP2A—Cytarabine—Gemcitabine—kidney cancer	6.06e-05	0.0409	CbGdCrCtD
Valrubicin—Flatulence—Capecitabine—kidney cancer	6.04e-05	0.00165	CcSEcCtD
Valrubicin—Dizziness—Sunitinib—kidney cancer	6e-05	0.00164	CcSEcCtD
Valrubicin—Feeling abnormal—Gemcitabine—kidney cancer	6e-05	0.00164	CcSEcCtD
Valrubicin—Vomiting—Sorafenib—kidney cancer	5.99e-05	0.00164	CcSEcCtD
Valrubicin—Rash—Sorafenib—kidney cancer	5.94e-05	0.00163	CcSEcCtD
Valrubicin—Dermatitis—Sorafenib—kidney cancer	5.94e-05	0.00163	CcSEcCtD
Valrubicin—Back pain—Capecitabine—kidney cancer	5.93e-05	0.00162	CcSEcCtD
Valrubicin—Headache—Sorafenib—kidney cancer	5.9e-05	0.00162	CcSEcCtD
Valrubicin—Diarrhoea—Dactinomycin—kidney cancer	5.87e-05	0.00161	CcSEcCtD
Valrubicin—Vomiting—Sunitinib—kidney cancer	5.77e-05	0.00158	CcSEcCtD
Valrubicin—Body temperature increased—Gemcitabine—kidney cancer	5.75e-05	0.00158	CcSEcCtD
Valrubicin—Rash—Sunitinib—kidney cancer	5.72e-05	0.00157	CcSEcCtD
Valrubicin—Dermatitis—Sunitinib—kidney cancer	5.71e-05	0.00156	CcSEcCtD
Valrubicin—Ill-defined disorder—Capecitabine—kidney cancer	5.68e-05	0.00156	CcSEcCtD
Valrubicin—Headache—Sunitinib—kidney cancer	5.68e-05	0.00156	CcSEcCtD
Valrubicin—Anaemia—Capecitabine—kidney cancer	5.66e-05	0.00155	CcSEcCtD
Valrubicin—Nausea—Sorafenib—kidney cancer	5.6e-05	0.00153	CcSEcCtD
Valrubicin—Doxorubicin—ABCB1—kidney cancer	5.56e-05	0.035	CrCbGaD
Valrubicin—Musculoskeletal discomfort—Paclitaxel—kidney cancer	5.55e-05	0.00152	CcSEcCtD
Valrubicin—Malaise—Capecitabine—kidney cancer	5.52e-05	0.00151	CcSEcCtD
Valrubicin—Asthenia—Vincristine—kidney cancer	5.5e-05	0.00151	CcSEcCtD
Valrubicin—Vomiting—Dactinomycin—kidney cancer	5.46e-05	0.0015	CcSEcCtD
Valrubicin—Rash—Dactinomycin—kidney cancer	5.41e-05	0.00148	CcSEcCtD
Valrubicin—Nausea—Sunitinib—kidney cancer	5.39e-05	0.00148	CcSEcCtD
Valrubicin—Dysuria—Doxorubicin—kidney cancer	5.3e-05	0.00145	CcSEcCtD
Valrubicin—Diarrhoea—Vincristine—kidney cancer	5.25e-05	0.00144	CcSEcCtD
Valrubicin—Pollakiuria—Doxorubicin—kidney cancer	5.24e-05	0.00143	CcSEcCtD
Valrubicin—Asthenia—Gemcitabine—kidney cancer	5.22e-05	0.00143	CcSEcCtD
Valrubicin—Myalgia—Capecitabine—kidney cancer	5.22e-05	0.00143	CcSEcCtD
Valrubicin—Chest pain—Capecitabine—kidney cancer	5.22e-05	0.00143	CcSEcCtD
Valrubicin—TOP2A—Idarubicin—Doxorubicin—kidney cancer	5.2e-05	0.0351	CbGdCrCtD
Valrubicin—TOP2A—Epirubicin—Doxorubicin—kidney cancer	5.2e-05	0.0351	CbGdCrCtD
Valrubicin—TOP2A—Daunorubicin—Doxorubicin—kidney cancer	5.2e-05	0.0351	CbGdCrCtD
Valrubicin—Discomfort—Capecitabine—kidney cancer	5.15e-05	0.00141	CcSEcCtD
Valrubicin—Pruritus—Gemcitabine—kidney cancer	5.15e-05	0.00141	CcSEcCtD
Valrubicin—Hyperglycaemia—Doxorubicin—kidney cancer	5.11e-05	0.0014	CcSEcCtD
Valrubicin—Nausea—Dactinomycin—kidney cancer	5.1e-05	0.0014	CcSEcCtD
Valrubicin—Pneumonia—Doxorubicin—kidney cancer	5.08e-05	0.00139	CcSEcCtD
Valrubicin—Dizziness—Vincristine—kidney cancer	5.07e-05	0.00139	CcSEcCtD
Valrubicin—Feeling abnormal—Paclitaxel—kidney cancer	5.02e-05	0.00138	CcSEcCtD
Valrubicin—Gastrointestinal pain—Paclitaxel—kidney cancer	4.98e-05	0.00136	CcSEcCtD
Valrubicin—Diarrhoea—Gemcitabine—kidney cancer	4.98e-05	0.00136	CcSEcCtD
Valrubicin—Urinary tract infection—Doxorubicin—kidney cancer	4.91e-05	0.00135	CcSEcCtD
Valrubicin—Vomiting—Vincristine—kidney cancer	4.88e-05	0.00134	CcSEcCtD
Valrubicin—Rash—Vincristine—kidney cancer	4.84e-05	0.00132	CcSEcCtD
Valrubicin—Dermatitis—Vincristine—kidney cancer	4.83e-05	0.00132	CcSEcCtD
Valrubicin—Haematuria—Doxorubicin—kidney cancer	4.82e-05	0.00132	CcSEcCtD
Valrubicin—Body temperature increased—Paclitaxel—kidney cancer	4.82e-05	0.00132	CcSEcCtD
Valrubicin—Abdominal pain—Paclitaxel—kidney cancer	4.82e-05	0.00132	CcSEcCtD
Valrubicin—Headache—Vincristine—kidney cancer	4.81e-05	0.00132	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—CTNNB1—kidney cancer	4.72e-05	0.0189	CbGpPWpGaD
Valrubicin—Vomiting—Gemcitabine—kidney cancer	4.63e-05	0.00127	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—SYNE2—kidney cancer	4.61e-05	0.0185	CbGpPWpGaD
Valrubicin—Rash—Gemcitabine—kidney cancer	4.59e-05	0.00126	CcSEcCtD
Valrubicin—Dermatitis—Gemcitabine—kidney cancer	4.58e-05	0.00126	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—HNF1B—kidney cancer	4.56e-05	0.0183	CbGpPWpGaD
Valrubicin—Headache—Gemcitabine—kidney cancer	4.56e-05	0.00125	CcSEcCtD
Valrubicin—Nausea—Vincristine—kidney cancer	4.56e-05	0.00125	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Capecitabine—kidney cancer	4.56e-05	0.00125	CcSEcCtD
Valrubicin—Oedema peripheral—Doxorubicin—kidney cancer	4.47e-05	0.00122	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—KCNMA1—kidney cancer	4.45e-05	0.0178	CbGpPWpGaD
Valrubicin—Asthenia—Paclitaxel—kidney cancer	4.37e-05	0.0012	CcSEcCtD
Valrubicin—TOP2A—Azacitidine—Gemcitabine—kidney cancer	4.35e-05	0.0293	CbGdCrCtD
Valrubicin—Nausea—Gemcitabine—kidney cancer	4.32e-05	0.00118	CcSEcCtD
Valrubicin—Pruritus—Paclitaxel—kidney cancer	4.31e-05	0.00118	CcSEcCtD
Valrubicin—Diarrhoea—Paclitaxel—kidney cancer	4.17e-05	0.00114	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—PSMD7—kidney cancer	4.16e-05	0.0167	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	4.15e-05	0.0167	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	4.15e-05	0.0167	CbGpPWpGaD
Valrubicin—Feeling abnormal—Capecitabine—kidney cancer	4.12e-05	0.00113	CcSEcCtD
Valrubicin—Gastrointestinal pain—Capecitabine—kidney cancer	4.09e-05	0.00112	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—kidney cancer	4.04e-05	0.0162	CbGpPWpGaD
Valrubicin—Dizziness—Paclitaxel—kidney cancer	4.03e-05	0.0011	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—JUND—kidney cancer	3.99e-05	0.016	CbGpPWpGaD
Valrubicin—Abdominal pain—Capecitabine—kidney cancer	3.95e-05	0.00108	CcSEcCtD
Valrubicin—Body temperature increased—Capecitabine—kidney cancer	3.95e-05	0.00108	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	3.94e-05	0.0158	CbGpPWpGaD
Valrubicin—Flatulence—Doxorubicin—kidney cancer	3.89e-05	0.00107	CcSEcCtD
Valrubicin—Vomiting—Paclitaxel—kidney cancer	3.87e-05	0.00106	CcSEcCtD
Valrubicin—Rash—Paclitaxel—kidney cancer	3.84e-05	0.00105	CcSEcCtD
Valrubicin—Dermatitis—Paclitaxel—kidney cancer	3.84e-05	0.00105	CcSEcCtD
Valrubicin—Back pain—Doxorubicin—kidney cancer	3.82e-05	0.00105	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—MYC—kidney cancer	3.82e-05	0.0153	CbGpPWpGaD
Valrubicin—Headache—Paclitaxel—kidney cancer	3.82e-05	0.00105	CcSEcCtD
Valrubicin—Ill-defined disorder—Doxorubicin—kidney cancer	3.66e-05	0.001	CcSEcCtD
Valrubicin—Anaemia—Doxorubicin—kidney cancer	3.65e-05	0.001	CcSEcCtD
Valrubicin—Nausea—Paclitaxel—kidney cancer	3.62e-05	0.000991	CcSEcCtD
Valrubicin—Asthenia—Capecitabine—kidney cancer	3.59e-05	0.000983	CcSEcCtD
Valrubicin—Malaise—Doxorubicin—kidney cancer	3.56e-05	0.000975	CcSEcCtD
Valrubicin—Pruritus—Capecitabine—kidney cancer	3.54e-05	0.000969	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	3.43e-05	0.0137	CbGpPWpGaD
Valrubicin—Diarrhoea—Capecitabine—kidney cancer	3.42e-05	0.000937	CcSEcCtD
Valrubicin—Chest pain—Doxorubicin—kidney cancer	3.36e-05	0.000921	CcSEcCtD
Valrubicin—Myalgia—Doxorubicin—kidney cancer	3.36e-05	0.000921	CcSEcCtD
Valrubicin—Discomfort—Doxorubicin—kidney cancer	3.32e-05	0.00091	CcSEcCtD
Valrubicin—Dizziness—Capecitabine—kidney cancer	3.31e-05	0.000906	CcSEcCtD
Valrubicin—Vomiting—Capecitabine—kidney cancer	3.18e-05	0.000871	CcSEcCtD
Valrubicin—Rash—Capecitabine—kidney cancer	3.15e-05	0.000864	CcSEcCtD
Valrubicin—Dermatitis—Capecitabine—kidney cancer	3.15e-05	0.000863	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	3.15e-05	0.0126	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 2—TP53—kidney cancer	3.14e-05	0.0126	CbGpPWpGaD
Valrubicin—Headache—Capecitabine—kidney cancer	3.13e-05	0.000858	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2B—kidney cancer	3.04e-05	0.0122	CbGpPWpGaD
Valrubicin—Nausea—Capecitabine—kidney cancer	2.97e-05	0.000814	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.94e-05	0.000804	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	2.83e-05	0.0113	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	2.83e-05	0.0113	CbGpPWpGaD
Valrubicin—Feeling abnormal—Doxorubicin—kidney cancer	2.66e-05	0.000728	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	2.64e-05	0.0106	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Doxorubicin—kidney cancer	2.64e-05	0.000722	CcSEcCtD
Valrubicin—Abdominal pain—Doxorubicin—kidney cancer	2.55e-05	0.000698	CcSEcCtD
Valrubicin—Body temperature increased—Doxorubicin—kidney cancer	2.55e-05	0.000698	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—EGR1—kidney cancer	2.54e-05	0.0102	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—kidney cancer	2.39e-05	0.00957	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	2.32e-05	0.00931	CbGpPWpGaD
Valrubicin—Asthenia—Doxorubicin—kidney cancer	2.31e-05	0.000633	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	2.3e-05	0.00923	CbGpPWpGaD
Valrubicin—Pruritus—Doxorubicin—kidney cancer	2.28e-05	0.000625	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	2.25e-05	0.00902	CbGpPWpGaD
Valrubicin—Diarrhoea—Doxorubicin—kidney cancer	2.21e-05	0.000604	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—kidney cancer	2.19e-05	0.00877	CbGpPWpGaD
Valrubicin—Dizziness—Doxorubicin—kidney cancer	2.13e-05	0.000584	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—kidney cancer	2.09e-05	0.00836	CbGpPWpGaD
Valrubicin—Vomiting—Doxorubicin—kidney cancer	2.05e-05	0.000561	CcSEcCtD
Valrubicin—Rash—Doxorubicin—kidney cancer	2.03e-05	0.000557	CcSEcCtD
Valrubicin—Dermatitis—Doxorubicin—kidney cancer	2.03e-05	0.000556	CcSEcCtD
Valrubicin—Headache—Doxorubicin—kidney cancer	2.02e-05	0.000553	CcSEcCtD
Valrubicin—Nausea—Doxorubicin—kidney cancer	1.91e-05	0.000524	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—kidney cancer	1.74e-05	0.00697	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—kidney cancer	1.67e-05	0.00671	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	1.62e-05	0.0065	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—kidney cancer	1.54e-05	0.00617	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PSMD7—kidney cancer	1.52e-05	0.00611	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—AURKA—kidney cancer	1.48e-05	0.00595	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—kidney cancer	1.47e-05	0.00588	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	1.37e-05	0.00551	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—PSMD7—kidney cancer	1.36e-05	0.00547	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—AURKA—kidney cancer	1.33e-05	0.00532	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.27e-05	0.0051	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.26e-05	0.00505	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.23e-05	0.00493	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—MYC—kidney cancer	1.18e-05	0.00472	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.17e-05	0.00467	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2B—kidney cancer	1.11e-05	0.00447	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.11e-05	0.00446	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.11e-05	0.00445	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.1e-05	0.00441	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.07e-05	0.0043	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—JUN—kidney cancer	1.07e-05	0.00427	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PTEN—kidney cancer	1.03e-05	0.00413	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BRCA2—kidney cancer	1e-05	0.00403	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2B—kidney cancer	9.96e-06	0.00399	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	9.69e-06	0.00389	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—BIRC5—kidney cancer	9.61e-06	0.00385	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	9.17e-06	0.00368	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	8.92e-06	0.00358	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	8.72e-06	0.0035	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BIRC5—kidney cancer	8.59e-06	0.00345	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	8.24e-06	0.0033	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	7.57e-06	0.00304	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	7.32e-06	0.00294	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TP53—kidney cancer	7.03e-06	0.00282	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—kidney cancer	6.37e-06	0.00255	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2A—kidney cancer	5.7e-06	0.00228	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1B—kidney cancer	5.64e-06	0.00226	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCND1—kidney cancer	5.38e-06	0.00216	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1B—kidney cancer	5.04e-06	0.00202	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCND1—kidney cancer	4.81e-06	0.00193	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—kidney cancer	4.44e-06	0.00178	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MYC—kidney cancer	4.32e-06	0.00173	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MAPK1—kidney cancer	4.22e-06	0.00169	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MAPK3—kidney cancer	3.97e-06	0.00159	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MYC—kidney cancer	3.86e-06	0.00155	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MAPK1—kidney cancer	3.78e-06	0.00151	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TP53—kidney cancer	3.17e-06	0.00127	CbGpPWpGaD
